CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1.CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.Superiority was established on both weight loss and HbA1c versus the individual components.In the trial, CagriSema appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies. Bagsværd, Denmark, 2 February 2026 – N ...